Biogen Inc BIIB

What the company does

Biogen Inc is a large-cap company in the Healthcare sector (Drug Manufacturers - General), with a market value of $37.0B, based in the USA.

It employs about 7,500 people and has been listed since Sep 16, 1991.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.

Cheap or expensive? priced in line with its group

Its price-to-earnings (P/E) is 44.5 versus 36.9 for the median of the Healthcare sector in our universe (25 companies) — priced in line with its group.

Revenue is growing 3% versus the same quarter last year.

On analysts' next-year forecasts the multiple drops to 13.2 — they expect higher earnings.

The average analyst price target is 247.32, 1% below the current price (their view, not ours).

The stock sits at 97% of its one-year range (0% = the low, 100% = the high).

The risks

• • Quarterly report in 3 days (2026-10-28) — a day the stock can move a lot.

Strengths

• ✅ Profitable — 4 of every 100 dollars of revenue stays as profit.
• ✅ Generates free cash flow — profit becomes cash in the bank.
• ✅ Most analysts rate it buy (24 vs 1).

What changed this week

Over the past week the stock rose 7.8% (for comparison: S&P 500 -0.4%, sector ETF XLV +1.4%).

It set a new one-year high this week.

This week's news

• Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains? finance.yahoo.com · 2026-10-23
  What the article says

  Biogen Inc. (BIIB) shares soared 5.3% in the last trading session to close at $253.84. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5.9% gain over the past four weeks. Biogen's share price gain can likely be attributed to the growing… source ↗

• Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release finance.yahoo.com · 2026-10-22
  What the article says

  Exelixis (EXEL) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful… source ↗

• Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release finance.yahoo.com · 2026-10-21
  What the article says

  Biogen Inc. (BIIB) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful… source ↗

• The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics finance.yahoo.com · 2026-10-21
  What the article says

  For Immediate Release Chicago, IL – October 21, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: BridgeBio Pharma BBIO,… source ↗

• RBC Capital names top healthcare stocks as sector upgraded to overweight finance.yahoo.com · 2026-10-20
  What the article says

  Investing.com -- RBC Capital has upgraded the Healthcare sector to Overweight from Market Weight, identifying 11 high-conviction stock ideas across therapeutics and non-therapeutics segments. The upgrade is supported by improving flows, positive earnings and sales revision profiles, and attractive valuations. RBC Head… source ↗

• 4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now finance.yahoo.com · 2026-10-20
  What the article says

  Biotechnology companies with promising late-stage drug pipelines can offer significant growth potential as experimental treatments move closer to commercialization. Positive phase III results and regulatory decisions can validate a drug candidate's efficacy, strengthen its commercial prospects and provide a potential… source ↗

What changed since last week

• The price rose 7.8% since the last summary.